Anemia in Chronic Kidney Disease Market Set for Significant Growth and Innovation by 2034
With improved awareness and screening, earlier diagnosis and intervention are becoming more achievable, especially with the support of emerging biomarkers and treatment guidelines. Innovative therapies such as HIF-PH inhibitors and long-acting erythropoiesis-stimulating agents (ESAs) are shaping a dynamic treatment landscape aimed at improving hemoglobin levels with fewer side effects.
DelveInsight's ' Anemia in Chronic Kidney Disease Market Report ' offers an in-depth analysis of the epidemiology, disease burden, and market outlook across key geographies, including the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report highlights current unmet needs, late-stage pipeline therapies, market drivers and barriers, and the key players transforming patient care, making it a vital resource for healthcare stakeholders and innovators in nephrology.
Some of the Key Facts of the Anemia in Chronic Kidney Disease Market Report:
• The anemia in chronic kidney disease is expected to grow at a significant CAGR by 2034.
• In 2023, the United States recorded the highest number of prevalent Anemia in Chronic Kidney Disease (CKD) cases among the 7MM.
• The U.S. also accounted for the highest number of treated cases of Anemia in CKD during the same year.
• A higher prevalence was noted among individuals aged 60 and above compared to those under 60 in the U.S.
• Males with CKD had a 30% higher risk of developing anemia compared to females.
• Among the EU4 and the UK, Spain reported the lowest number of anemia in CKD cases in 2023.
• In Japan, anemia was one of the most frequently documented outcomes, with prevalence rates ranging from 0% to 95%, depending on CKD severity and dialysis status.
• In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including nephrotic syndrome.
• In March 2025, scPharmaceuticals received FDA approval for a supplemental new drug application (sNDA) for Furoscix (furosemide injection). This approval expands the drug's use to treat edema in patients with chronic kidney disease (CKD), marking a significant advancement in scPharmaceuticals' portfolio for cardiorenal conditions.
• In March 2025, the FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to treat edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025. This approval follows the FDA's acceptance of the supplemental new drug application in July 2024.
• In January 2025, the FDA approved a new indication for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk.
• In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a PDUFA target action date set for June 28, 2025. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis.
• Leading companies in the anemia in chronic kidney disease market include Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others.
• Emerging therapies in the anemia in chronic kidney disease market include DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others.
• The rising prevalence of anemia in chronic kidney disease, along with continuous advancements in therapeutic options, is fueling the demand for more effective treatment approaches.
To know in detail about the anemia in chronic kidney disease market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Anemia In Chronic Kidney Disease Market Forecast
Anemia in Chronic Kidney Disease Overview
Anemia is a frequent and serious complication of Chronic Kidney Disease (CKD), arising as kidney function declines and the body's ability to produce adequate erythropoietin—a hormone essential for red blood cell production, diminishes. CKD impairs the kidneys' filtering ability, leading to the accumulation of waste and fluids, which further contributes to the onset of anemia.
The condition becomes increasingly prevalent in advanced stages of CKD. In the United States, over 37 million adults are estimated to have CKD, and more than one in seven individuals with CKD also suffer from anemia. The risk intensifies as kidney function deteriorates, with nearly all individuals at end-stage kidney failure (when kidney function drops below 15%) experiencing anemia.
Certain populations are more susceptible: individuals with CKD and diabetes are at higher risk of developing anemia earlier and in more severe forms. Additionally, people over the age of 60 are more likely to be affected. The progression of CKD-related anemia is typically gradual and may remain asymptomatic in its early stages, making early detection and management crucial for improving patient outcomes.
Get a free sample of the anemia in chronic kidney disease market report with key insights and emerging therapies here:
Anemia in Chronic Kidney Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Anemia in Chronic Kidney Disease Epidemiology Segmentation:
The anemia in chronic kidney disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Total Prevalent Cases of Chronic Kidney Disease
• Diagnosed Cases of Anemia in Chronic Kidney Disease
• Age-Specific Prevalent Cases of Anemia in Chronic Kidney Disease
• Total Prevalent Cases of Anemia in Chronic Kidney Disease
• Total Prevalent Cases of Anemia in Different Stages of Chronic Kidney Disease
• Treatable Cases of Anemia in Chronic Kidney Disease
Download the report to understand which factors are driving anemia in chronic kidney disease epidemiology trends @ Anemia In Chronic Kidney Disease Epidemiology Forecast
The anemia in chronic kidney disease drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the anemia in chronic kidney disease market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.
Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.
The report further delves into the anemia in chronic kidney disease pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.
Anemia in Chronic Kidney Disease Market Strengths
• The availability of novel oral treatment options, such as daprodustat, offers more convenient and effective routes of administration for patients.
• Active research and ongoing clinical trials are enhancing the understanding of the disease and driving innovation in therapeutic strategies.
Anemia in Chronic Kidney Disease Market Weaknesses
• Patients often struggle to recognize or differentiate the symptoms of anemia from CKD or other related conditions, leading to underreporting.
• Healthcare providers, particularly in non-dialysis settings, frequently under-monitor hemoglobin levels and iron stores, resulting in delayed or suboptimal treatment initiation.
Scope of the Anemia in Chronic Kidney Disease Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Anemia In Chronic Kidney Disease Companies: GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others.
• Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others.
• Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia in chronic kidney disease, currently marketed, and anemia in chronic kidney disease emerging therapies
• Anemia In Chronic Kidney Disease Market Dynamics: Anemia in chronic kidney disease market drivers and anemia in chronic kidney disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Anemia In Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Anemia In Chronic Kidney Disease Market Access and Reimbursement
To learn more about the key players and advancements in the anemia in chronic kidney disease treatment landscape, visit the
Table of Contents
1. Anemia In Chronic Kidney Disease Market Report Introduction
2. Executive Summary for Anemia In Chronic Kidney Disease
3. SWOT analysis of Anemia In Chronic Kidney Disease
4. Anemia In Chronic Kidney Disease Patient Share (%) Overview at a Glance
5. Anemia In Chronic Kidney Disease Market Overview at a Glance
6. Anemia In Chronic Kidney Disease Disease Background and Overview
7. Anemia In Chronic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Anemia In Chronic Kidney Disease
9. Anemia In Chronic Kidney Disease Current Treatment and Medical Practices
10. Anemia In Chronic Kidney Disease Unmet Needs
11. Anemia In Chronic Kidney Disease Emerging Therapies
12. Anemia In Chronic Kidney Disease Market Outlook
13. Country-Wise Anemia In Chronic Kidney Disease Market Analysis (2020–2034)
14. Anemia In Chronic Kidney Disease Market Access and Reimbursement of Therapies
15. Anemia In Chronic Kidney Disease Market Drivers
16. Anemia In Chronic Kidney Disease Market Barriers
17. Anemia In Chronic Kidney Disease Appendix
18. Anemia In Chronic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
16 hours ago
- CTV News
Assiniboine Park Zoo mourns death of red panda
Sachi, a red panda at the Assiniboine Park Zoo, in an undated image. Uploaded on July 30, 2025. (Assiniboine Park and Zoo/Facebook) The Assiniboine Park Zoo is mourning the loss of one of its red pandas. Sachi, a beloved red panda, arrived at the zoo in July 2014 after being born in Nagano, Japan in 2012. 'Sachi has been receiving veterinary care for a number of years to address gastrointestinal disturbances,' said the Assiniboine Park Zoo in a Facebook post Monday. 'While treatment was typically effective to help resolve her symptoms, over recent months these disturbances increased in frequency and intensity.' The zoo said her health recently took a turn for the worse and after a thorough examination, the veterinary team determined 'humane euthanasia was the best course of action.' Post-mortem examinations and testing also revealed that Sachi was experiencing changes in heart health as she aged, having surpassed the ten-year median life expectancy for red pandas in care. Sachi, a red panda at the Assiniboine Park Zoo, in an undated image. Uploaded on July 30, 2025. (Assiniboine Park and Zoo/Facebook) Sachi, a red panda at the Assiniboine Park Zoo, in an undated image. Uploaded on July 30, 2025. (Assiniboine Park and Zoo/Facebook) The zoo said Sachi was an 'excellent ambassador for her species' during her time at the zoo, helping to educate visitors on the challenges facing endangered species in the wild. A spokesperson for the zoo said they currently have four red pandas—two of which are surviving offspring from Sachi and her partner, Tango. 'Sachi touched many lives and was cared for by several animal care professionals here at the zoo who will all greatly miss her and her cute curly tail,' said the zoo. Red pandas are found in the mountain forests of Nepal, Bhutan, India, China, and Myanmar, according to the zoo.
Globe and Mail
a day ago
- Globe and Mail
Sleep Apnea Pipeline Outlook Report 2025: Key 10+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Sleep Apnea Pipeline Insight, 2025' report provides comprehensive insights about 10+ companies and 14+ pipeline drugs in Sleep Apnea pipeline landscape. It covers the Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Sleep Apnea Treatment Landscape. Click here to read more @ Sleep Apnea Pipeline Outlook Key Takeaways from the Sleep Apnea Pipeline Report In July 2025, Mineralys Therapeutics Inc. announced a study is a randomized, double-blind (DB), placebo controlled, crossover study. A 4-week screening period is followed by two DB 4-week treatment periods separated by a 2-week washout period. Participants must be 18 to 75 years old with moderate to severe OSA, hypertension and meet all applicable eligibility criteria. Participants who are medically prescribed and deemed compliant with positive airway pressure (PAP) therapy for greater than or equal to (>=) 4 hours per night (Continuous PAP [CPAP], or automatic PAP [autoPAP]) and for at least 3 months prior to the study enrollment are eligible for the study. In July 2025, Eli Lilly and Company announced a study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. DelveInsight's Sleep Apnea pipeline report depicts a robust space with 10+ active players working to develop 14+ pipeline therapies for Sleep Apnea treatment. The leading Sleep Apnea Companies such as Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Promising Sleep Apnea Pipeline Therapies such as Sivopixant, Acetazolamide, SAS0421a, VI-0521, Zonisamide, Sulthiame, AD128, BAY2586116 and others. Stay informed about the cutting-edge advancements in Sleep Apnea Treatments. Download for updates and be a part of the revolution in dermatology care @ Sleep Apnea Clinical Trials Assessment Sleep Apnea Emerging Drugs Profile AD109: Apnimed AD109 is an investigational oral therapy, a pill designed to target the underlying neuromuscular dysfunction in people living with mild, moderate, and severe obstructive sleep apnea (OSA). This novel treatment targets the hypoglossal motor nucleus (HMN) to increase signals in the upper airway dilator muscles during sleep to limit or prevent airway collapse. It is a potential first-in-class, novel, investigational combination dosed once daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines company's novel selective antimuscarinic (aroxybutynin) with a selective norepinephrine reuptake inhibitor (atomoxetine). AD109 targets key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep. AD109 has the potential to become a safe, effective, and convenient treatment for OSA, addressing some of the key limitations of current standard of care treatments that can be poorly tolerated (e.g., CPAP and oral devices) and/or invasive (e.g., surgery or implanted devices). Currently, the drug is in the Phase III stage of its development for the treatment of Obstructive Sleep Apnea. Dronabinol: RespireRx Phamaceuticals Dronabinol is a synthetic form of tetrahydrocannabinol (THC), the active compound in cannabis, primarily used to treat nausea, vomiting, and appetite loss. Research has shown potential for dronabinol in treating sleep apnea by stimulating the body's endocannabinoid receptors, which may help reduce apnea episodes and stabilize breathing during sleep. While not yet FDA-approved for sleep apnea, clinical studies suggest it could be beneficial in managing obstructive sleep apnea (OSA) symptoms. Currently, the drug is in the Phase II stage of its development for the treatment of Sleep Apnea. Gal 475: Neurim Pharmaceuticals GAL-475 is a novel therapeutic agent for the treatment of sleep apnea syndromes. In a series of in vitro and in vivo studies in various animal models it demonstrated improvements in sleep apnea indices with reductions in both the frequency and severity of events, without stimulating minute ventilation or disturbing sleep. Preclinical pharmacology studies with GAL-475 suggest that the compound acts predominantly as a peripheral chemoreception modulator, and indicate that the compound is effective in increasing respiratory drive to the upper airways and ameliorating obstructive apneas and their attendant sequelae in rodent models of obstructive apnea at relatively low plasma levels. The primary site of action for GAL-475 appears to be at the level of the carotid body, a peripheral polymodal chemosensory organ, located at the carotid bifurcation, responsible for sensing changes in partial pressures of O2, CO2 or pH, and activating the brainstem respiratory center to produce hyperventilation. Currently, the drug is in the Phase I stage of its development for the treatment of Sleep Apnea. The Sleep Apnea pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Sleep Apnea with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sleep Apnea Treatment. Sleep Apnea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sleep Apnea market. Get a detailed analysis of the latest innovations in the Sleep Apnea pipeline. Explore DelveInsight's expert-driven report today! @ Sleep Apnea Unmet Needs Sleep Apnea Companies Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Sleep Apnea Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Sleep Apnea Treatment by visiting our website. Stay informed about how we're transforming the future of Dermatology @ Sleep Apnea Market Drivers and Barriers, and Future Perspectives Scope of the Sleep Apnea Pipeline Report Coverage- Global Sleep Apnea Companies- Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Phamaceuticals, Neurim Pharmaceuticals and others. Sleep Apnea Pipeline Therapies- Sivopixant, Acetazolamide, SAS0421a, VI-0521, Zonisamide, Sulthiame, AD128, BAY2586116 and others. Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Sleep Apnea Pipeline on our website @ Sleep Apnea Emerging Drugs and Companies Table of Contents Introduction Executive Summary Sleep Apnea: Overview Pipeline Therapeutics Therapeutic Assessment Sleep Apnea– DelveInsight's Analytical Perspective Late Stage Products (Phase III) AD109: Apnimed Drug profiles in the detailed report….. Mid Stage Products (Phase II) Dronabinol: RespireRx Phamaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) Gal 475: Neurim Pharmaceuticals Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Sleep Apnea Key Companies Sleep Apnea Key Products Sleep Apnea- Unmet Needs Sleep Apnea- Market Drivers and Barriers Sleep Apnea- Future Perspectives and Conclusion Sleep Apnea Analyst Views Sleep Apnea Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
2 days ago
- Globe and Mail
JAK Inhibitors Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, ' Janus Kinase (JAK) Inhibitor Pipeline Insight, 2025 ' report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the JAK Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the JAK Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the JAK Inhibitors Treatment Landscape. Click here to read more @ JAK Inhibitors Pipeline Outlook Key Takeaways from the JAK Inhibitors Pipeline Report In June 2025, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announced a study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care. DelveInsight's JAK Inhibitors pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for JAK Inhibitors treatment. The leading JAK Inhibitors Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. Promising JAK Inhibitors Pipeline Therapies such as Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others. Stay informed about the cutting-edge advancements in JAK Inhibitors Treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ JAK Inhibitors Clinical Trials Assessment JAK Inhibitors Emerging Drugs Profile Povorcitinib: Incyte Corporation Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo. CPL409116: Celon Pharma CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL'116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease. ATI-2138: Aclaris Therapeutics ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities. SDC 1802: Sareum SDC-1802 is an investigational Sareum's TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer. The JAK Inhibitors pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of JAK Inhibitors with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for JAK Inhibitors Treatment. JAK Inhibitors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. JAK Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the JAK Inhibitors market. Get a detailed analysis of the latest innovations in the JAK Inhibitors pipeline. Explore DelveInsight's expert-driven report today! @ JAK Inhibitors Unmet Needs JAK Inhibitors Companies Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. Janus Kinase (JAK) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical JAK Inhibitors Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in JAK Inhibitors Treatment by visiting our website. Stay informed about how we're transforming the future of Immunological and Autoimmune Disorders @ JAK Inhibitors Market Drivers and Barriers, and Future Perspectives Scope of the JAK Inhibitors Pipeline Report Coverage- Global JAK Inhibitors Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. JAK Inhibitors Pipeline Therapies- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others. JAK Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination JAK Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of JAK Inhibitors Pipeline on our website @ JAK Inhibitors Emerging Drugs and Companies Table of Contents Introduction Executive Summary Janus Kinase (JAK) Inhibitor: Overview Pipeline Therapeutics Therapeutic Assessment Janus Kinase (JAK) Inhibitor– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Povorcitinib: Incyte Corporation Drug profiles in the detailed report….. Mid Stage Products (Phase II) CPL409116: Celon Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) ATI-2138: Aclaris Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products SDC 1802: Sareum Drug profiles in the detailed report….. Inactive Products Janus Kinase (JAK) Inhibitor Key Companies Janus Kinase (JAK) Inhibitor Key Products Janus Kinase (JAK) Inhibitor- Unmet Needs Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion Janus Kinase (JAK) Inhibitor Analyst Views Janus Kinase (JAK) Inhibitor Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
